What is Zacks Research’s Estimate for TEVA Q1 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Stock analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Teva Pharmaceutical Industries in a research report issued on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.48 for the quarter, up from their prior forecast of $0.46. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.34 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q2 2025 earnings at $0.59 EPS, Q1 2026 earnings at $0.48 EPS and Q3 2026 earnings at $0.82 EPS.

Other equities analysts have also recently issued reports about the company. UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays increased their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.65 on Monday. The stock has a market cap of $18.86 billion, a PE ratio of -19.59, a P/E/G ratio of 1.30 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a twelve month low of $9.35 and a twelve month high of $19.31. The stock has a fifty day simple moving average of $17.54 and a 200-day simple moving average of $17.36.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Sanctuary Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 0.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after acquiring an additional 805 shares in the last quarter. Smithfield Trust Co raised its position in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares in the last quarter. Signaturefd LLC raised its position in shares of Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after acquiring an additional 1,094 shares in the last quarter. Finally, Bridgewater Associates LP raised its position in shares of Teva Pharmaceutical Industries by 5.2% during the 3rd quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock worth $418,000 after acquiring an additional 1,144 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.